Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Interferon Market: By Disease Treated (Hepatitis-B, Hepatitis C, Melanoma, Leukemia (Interferon Alpha), By Multiple Sclerosis (Interferon Beta), Renal Cell Carcinoma, Leukemia (Interferon Gamma)) By Geography-Forecast 2019-2024

Published by IndustryARC Product code 422051
Published Content info
Delivery time: 2-3 business days
Back to Top
Interferon Market: By Disease Treated (Hepatitis-B, Hepatitis C, Melanoma, Leukemia (Interferon Alpha), By Multiple Sclerosis (Interferon Beta), Renal Cell Carcinoma, Leukemia (Interferon Gamma)) By Geography-Forecast 2019-2024
Published: December 18, 2018 Content info:

Interferons can be defines and segmented as a class of proteins generated and released by the host cells against the presence of pathogenic microbes like bacteria, viruses, fungi and tumor cells. Interferon proteins belong to a class of glycoproteins namely cytokines and are is generally considered to be the first line of defence against any microbial infections. Due to the ability of interferons to 'interfere in viral cell replication', these proteins can fight against an infection by triggering an immune response, which results in the generation of immunologic cells, like T-cells, natural killer cells and macrophages. Interferon therapy is identified as one of the most advanced and effective clinical methods for treatment of numerous diseases like hepatitis, sclerosis and cancer.

This report identifies the interferon market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to interferon market.

Globally North America dominated the market for interferon in 2015 with highest market share due to higher awareness about such advanced treatment therapies amongst its citizens coupled with developed medical and healthcare establishment and availability of experts in the region. North America was followed by Europe and Asia-Pacific as the second and third largest regional market respectively, for interferon. However, Asia-Pacific is expected to be fastest growing regional segment during the period of study due to fast growing healthcare setup in the region especially in India and China along with growing awareness about the interferon therapy in the region.

This report on global interferon covers different type of diseases treated by using interferon therapy and market size in various geographical regions.

On the basis of diseases treated with the interferon therapy, this report is segmented into seven major segments as follows: Hepatitis-B, Hepatitis C, Melanoma, Leukemia (Interferon Alpha), Multiple Sclerosis (Interferon Beta), Renal Cell Carcinoma and Leukemia (Interferon Gamma)

This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for interferon in each of the region.

This report identifies all the major companies operating in the global interferon market. Some of the major companies' profiles in detail are as follows:

Merck & Co.,Inc.

Changchun Institute of Biological Products

Bristol-Myers Squibb

Novartis AG

Schering-Plough Corporation.

Table of Contents

Table of Contents

1. Interferon - Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End User Profiling
    • 3.2.3. Top 5 Financials Analysis

4. Interferon - Market Forces

  • 4.1. Drivers
    • 4.1.1. Increasing awareness about interferon therapy in developing economies
    • 4.1.2. Continuous R&D activities
  • 4.2. Restraints
    • 4.2.1. High Cost
  • 4.3. Opportunities
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Interferon - Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Interferon Market, By Disease Treated

  • 6.1. Hepatitis-B
  • 6.2. Hepatitis C
  • 6.3. Melanoma
  • 6.4. Leukemia (Interferon Alpha)
  • 6.5. Multiple Sclerosis (Interferon Beta)
  • 6.6. Renal Cell Carcinoma
  • 6.7. Leukemia (Interferon Gamma)

7. Interferon Market, By Geography

  • 7.1. Europe
    • 7.1.1. Germany
    • 7.1.2. France
    • 7.1.3. Italy
    • 7.1.4. Spain
    • 7.1.5. Russia
    • 7.1.6. U.K.
    • 7.1.7. Rest of Europe
  • 7.2. Asia Pacific
    • 7.2.1. China
    • 7.2.2. India
    • 7.2.3. Japan
    • 7.2.4. South Korea
    • 7.2.5. Rest of Asia-Pacific
  • 7.3. North America
    • 7.3.1. U.S.
    • 7.3.2. Canada
    • 7.3.3. Mexico
  • 7.4. Rest of the World (RoW)
    • 7.4.1. Brazil
    • 7.4.2. Rest of RoW

8. Interferon - Market Entropy

  • 8.1. Expansion
  • 8.2. Technological Developments
  • 8.3. Merger & Acquisitions, and Joint Ventures
  • 8.4. Supply- Contract

9. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)

  • 9.1. Merck & Co.,Inc.
  • 9.2. Changchun Institute of Biological Products
  • 9.3. Bristol-Myers Squibb
  • 9.4. Novartis AG
  • 9.5. Schering-Plough Corporation
  • 9.6. Serono
  • 9.7. Biogen Inc.
  • 9.8. Roche Inc.
  • 9.9. CR Double-Crane Pharmaceuticals
  • 9.10. Livzon Pharmaceutical Group

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

10. Appendix

  • 10.1. Abbreviations
  • 10.2. Sources
  • 10.3. Research Methodology
  • 10.4. Expert Insights
Back to Top